Title:Targeting Mutant KRAS for Anticancer Therapy
VOLUME: 19 ISSUE: 23
Author(s):Fengqian Chen, Martin P. Alphonse, Yan Liu and Qi Liu*
Affiliation:Department of Environmental Toxicology, The Institute of Environmental and Human Health (TIEHH), Texas Tech University, Lubbock, TX 79416, Department of Dermatology, Johns Hopkins University School of Medicine, Cancer Research Building II, Suite 216, 1550 Orleans Street, Baltimore, MD 21231, Western University of Health Sciences, 309 E. Second Street, Pomona, CA 91766, Department of Dermatology, Johns Hopkins University School of Medicine, Cancer Research Building II, Suite 216, 1550 Orleans Street, Baltimore, MD 21231
Keywords:KRAS mutant, KRAS pathway, Anticancer therapeutics, Cell signaling, Guanosine triphosphate-bound RAS, Oncogene.
Abstract:Over the past decades, designing therapeutic strategies to target KRAS-mutant cancers, which
is one of the most frequent mutant oncogenes among all cancer types, have proven unsuccessful regardless
of many concerted attempts. There are key challenges for KRAS-mutant anticancer therapy, as the
complex cellular processes involved in KRAS signaling has present. Herein, we highlight the emerging
therapeutic approaches for inhibiting KRAS signaling and blocking KRAS functions, in hope to serve as
a more effective guideline for future development of therapeutics.